Xilio Therapeutics Cash Flow Statement (2024-2025) | XLO

Cash Flow Statement Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Operating Activities
Net Income -14.70M-14.76M-13.63M-13.85M-14.37M-1.93M
Depreciation and Depletion 0.40M0.40M0.40M0.40M0.50M0.40M0.30M
Share-based Compensation 1.83M1.51M1.57M1.52M1.53M1.35M1.12M
Gains from Sales and Divestitures 0.00M0.01M0.01M0.01M0.11M0.11M0.11M
Gains from Investment Securities 0.02M8.04M8.01M10.86M11.45M11.51M
Non-cash Items 0.31M3.44M0.10M0.28M4.53M0.04M6.45M
Cash from Operations -10.50M19.95M-13.67M-14.16M28.98M-14.48M-17.50M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF) 0.44M0.45M0.38M0.38M0.50M0.38M0.34M
Change in Working Capital
Change in Receivables 30.00M
Change in Account Payables -0.30M0.51M-0.28M1.60M-0.59M2.11M-1.80M
Change in Accured Expenses -2.50M1.25M-0.21M0.96M-6.10M0.88M3.31M
Other Working Capital Changes 39.12M-2.36M-2.26M-1.72M46.21M-8.08M-1.56M
Investing Activities
Capital Expenditures 0.02M0.01M0.01M0.29M0.13M
Cash from Investing Activities -0.01M-0.01M-0.02M-0.40M
Financing Activities
Cash from Financing Activities 0.95M20.04M-0.00M8.20M4.83M47.36M-0.28M
Additional items
Change in Cash -9.55M39.98M-13.68M-5.96M33.79M32.48M-17.78M
Free Cash Flow -10.52M19.95M-13.68M-14.16M28.69M-14.61M-17.50M
Net Cash Flow -9.55M40.00M-13.68M-5.96M33.79M32.48M-17.78M